Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $119.22

Ascendis Pharma A/S (NASDAQ:ASND)’s share price gapped up before the market opened on Monday . The stock had previously closed at $119.22, but opened at $139.65. Ascendis Pharma A/S shares last traded at $143.83, with a volume of 357,706 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ASND shares. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Citigroup dropped their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Wells Fargo & Company lowered their target price on Ascendis Pharma A/S from $277.00 to $264.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. Stifel Nicolaus assumed coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They issued a “buy” rating and a $200.00 price objective for the company. Finally, TD Cowen cut their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $187.08.

Ascendis Pharma A/S Price Performance

The company has a 50 day moving average of $132.45 and a 200-day moving average of $136.53. The company has a market cap of $8.15 billion, a P/E ratio of -14.97 and a beta of 0.63.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of ASND. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Ascendis Pharma A/S by 1.1% during the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after purchasing an additional 44,580 shares during the last quarter. Capital International Investors boosted its holdings in shares of Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after buying an additional 93,185 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.